Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Clinical Trial Size in Orphan and Rare Diseases

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Dec 01, 2023 2:45pm

109 Views

Post# 35764112

RE:RE:RE:Clinical Trial Size in Orphan and Rare Diseases

so, ONCY has had 8 years to work with EMA to understand what reduced trial they can run... it hasn't happened, because ONCY have yet to prove statsically that increased T-Cell clonality translates to clinical benefit, which would support its use as a biomarker, for a potential accelerated approval

NOTE how Matt even stated this year that the mBC trial will be traditional 2 arm study... i.e 450 patients or so, and 3-4 years...

Pathetic

<< Previous

Bullboard Posts

Next >>

New CEO leads Sonoro Energy's vision to expand in MENA